Thomas Piemonte, MD
Interventional Cardiology · Burlington, MANPI 1225134067
Payments from drug & device makers
What this record shows
This record is dominated by other: $201,199 of the $330,466 with a category attached, or 60.9%. 8 manufacturers reported payments, led by Zimmer Biomet at 56.1% of the total. Reporting peaked in 2024 at $187,774 and has fallen 97.7% since, to $4,265 in 2025. Among interventional cardiology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $3553.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$185K
- Anika Therapeutics, Inc.$85K
- Abbott$49K
- Spirus Medical LLC$8K
- Edwards Lifesciences$2K
- Primo Medical Group, Inc. (f.k.a. STD Med Inc.)$1K
- plus $219 from 2 others
What the payments were for
- Royalty or licence$8,0102%
- Consulting fees$43,87513%
- Speaking & faculty fees$2,5751%
- Travel & lodging$3,2901%
- Food & beverage$2,2111%
- Gifts$840%
- Ownership interest$69,22321%
- Other$201,19961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 1 | $185,259 |
| Anika Therapeutics, Inc. | 4 | $85,163 |
| Abbott | 63 | $48,600 |
| Spirus Medical LLC | 7 | $8,149 |
| Edwards Lifesciences | 15 | $1,952 |
| Primo Medical Group, Inc. (f.k.a. STD Med Inc.) | 1 | $1,125 |
| Medtronic | 1 | $135 |
| Chiesi USA, Inc. | 1 | $84 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$330,466 in reported general payments places this provider in the 95th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 18 | $485 |
| Rosuvastatin Calcium | 15 | $401 |
| Losartan Potassium | 30 | $293 |
| Atorvastatin Calcium | 15 | $118 |
| Amlodipine Besylate | 31 | $96 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Burlington
- Sergio WaxmanBurlington$148K
- Sareena GeorgeBurlington$58K
- Frederic ResnicBurlington$29K
- Michael LevyBurlington$5K
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Suzanne BaronBoston$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.